The FDA has approved Vykat XR (diazoxide choline) for the treatment of hyperphagia in adults and pediatric patients 4 years ...

The United States Food and Drug Administration (US FDA) has approved VYKAT™ XR, a significant milestone as the first approved treatment for hyperphagia in Prader-Willi syndrome (PWS).

Federal regulators are clearing a first-of-its-kind treatment for symptoms of a rare neurodevelopmental disorder that is ...

The United States Food and Drug Administration (US FDA) has approved VYKAT™ XR, as the first approved treatment for hyperphagia in Prader-Willi syndrome (PWS). IPWSO hopes the US FDA approval is the ...

A new drug could change everything for children like seven-year-old daughter, Liliana, who has Prader-Willi syndrome, a rare ...

Lead candidate ARD-101 demonstrated clinical activity and was generally well tolerated in a two-part Phase 2 trial in Prader-Willi Syndrome (PWS), with meaningful reductions in hyperphagia (up to a 16 ...

According to Theratechnologies, Egrifta WR is set to replace Egrifta SV. The Food and Drug Administration (FDA) has approved Egrifta WR ™, a new concentrated formulation (F8) of tesamorelin, for ...

Microsoft is trying to clear that up with a new roadmap site. The dedicated page shows a long list of features in development, indicating which ones are currently in the Windows Insider Program ...

There has been a well-publicised boom in biotech investment during the pandemic, and the UK is no exception, with a record £1 billion raised in the third quarter. Latest figures from the ...

Although achondroplasia and hypochondroplasia are considered distinct clinical diagnoses, they share a significant amount of overlapping features, according to a poster presented at the 2025 American ...